XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Balance Sheet Components - Additional Information (Detail) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Jul. 31, 2021
Schedule of Available-for-sale Securities [Line Items]        
Cash and cash equivalents $ 105,734,000   $ 113,688,000  
Impairment loss 0 $ 0    
API and bulk drug product price true-up 57,370,000   50,978,000  
Accrued inventory related cost 8,521,000   0  
Accrued litigation settlement 28,500,000   28,500,000  
Net unbilled co-development revenue 0   0  
Litigation settlement receivable 28,500,000   28,500,000  
Eluminex Agreements [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Aggregate consideration received for milestone and upfront payments 4,000,000   4,000,000 $ 8,000,000
AstraZeneca Agreements [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Due to related parties 11,500,000      
Inventory write-down 12,600,000      
Net unbilled co-development revenue 22,900,000   22,500,000  
Foreign subsidiaries [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Cash and cash equivalents $ 27,600,000   $ 32,200,000